IL17A and inflammatory bowel disease: Vidofludimus is an oral immunosuppressant that can downregulate IL-17A and IL-17F levels by inhibiting STAT3 and NF-κB, demonstrating safety, efficacy and tolerability in hormone-dependent IBD patients (136).